bluuebunny/crossref_metadata_2025_split huggingface dataset:
An Unusual Presentation of Secondary Involvement of B-Cell Chronic Lymphocytic Leukemia. A Case Report
Authors: Famà Fausto , Barresi Valeria , Giuffrè Giuseppe , Todaro Paolo , Mazzei Sergio , Vindigni Angelo , Gioffrè-Florio Maria 
Published: February 2018

Extramammary tumors rarely metastasize to the breast. The commonest tumors to metastasize in breast tissue are lymphoproliferative diseases, melanoma, lung cancer and gynecological malignancies. Primary breast lymphoma has been reported in the literature with a maximum percentage of about 0.5% of all breast malignancies, while secondary localizations of lymphomas in the breast are less well studied in the literature than primary ones. The authors report a rare case of a secondary localization of B-cell chronic lymphocytic leukemia to the breast in which the diagnosis was obtained by histopathology and immunohistochemistry and further confirmed by molecular data. This occurrence must be considered in the differential diagnosis of a breast lump so that the primary hematological disease can be adequately treated and the correct type of breast surgery performed.
Insight into long-term histological, proliferative and apoptotic modifications in ileal orthotopic neobladder and conduit mucosa
Authors: Dellis Athanasios E , Demonakou Maria , Papatsoris Athanasios G , Chrisofos Michail , Bamias Aris , Deliveliotis Charalambos 
Published: February 2018

Aims and background To assess the long-term histological, apoptotic and proliferating alterations of the intestinal mucosa of ileal conduits and orthotopic neobladders. Methods Fifty patients (46 males, 4 females), aged 52–78 years, who underwent urinary diversion with either ileal orthotopic neobladder (group ON, 20 patients) or conduit (group IC, 30 patients) from 2001 to 2005, were included in this prospective study Ileal samples were collected during surgery (controls) and by random mucosal biopsies 6, 12, 24, 36 and 48 months later. Histological (villi height, crypt depth, eosinophil cell count), proliferation (Ki67 immunochemistry), and apoptotic (Bcl-2 immunochemistry TUNEL) parameters were assessed. Results During the 4-year follow-up, we recorded progressive villi area, height and crypt depth reduction, mucosa flattening, and inflammatory and eosinophilic infiltration. Villi height: crypt depth ratio showed a statistically significant difference ( P <0.05) between the two groups from the 6th month. Dysplasia, metaplasia, and neoplasia were not observed. Bcl-2 values showed a progressive increase until 24 months in group ON and 12 months in group IC, followed by a decline thereafter. Ki-67 values showed a progressive increase after 6 months in group ON and an increase until 24 months followed by a decline thereafter in group IC. TUNEL showed two peaks, at 24 and 48 months. Conclusions Histological adaptation was revealed in both groups, with statistically significant differences in favor of orthotopic substitution. Proliferative and apoptotic pathways are implicated as demonstrated by relevant modifications of Bcl-2, Ki-67 and TUNEL, in accord with the histological adaptation.
Gastric Cancer Mortality Trends in Tuscany, Italy, 1971–2004
Authors: Gorini Giuseppe , Giovannetti Lucia , Masala Giovanna , Chellini Elisabetta , Martini Andrea , Mallone Sandra , Costantini Adele Seniori 
Published: February 2018

Aims, Background, and Methods In Tuscany, Italy, gastric cancer mortality has been decreasing since 1950, although with relevant geographical variability across the region. In Eastern Tuscan areas close to the mountains (high risk areas), gastric cancer mortality has been and is still significantly higher than that recorded in Western coastal areas and in the city of Florence (low risk areas). High-risk areas also showed higher Helicobacter pylori seroprevalence. Aim of this paper is to study gastric cancer mortality trends in high and low-risk areas, during the period 1971–2004, using age-period-cohort models. Results In high-risk areas, gastric cancer mortality rates declined from 61.4 per 100,000 in 1971–74 to 19.8 in 2000–2004 and in low-risk areas from 34.9 to 9.8. Mortality decline in high-risk areas was mainly attributable to a birth cohort effect, whereas in low-risk areas it was due either to a birth cohort effect or a period effect. In low- and high-risk areas, birth-cohort risks of dying decreased over subsequent generations, except for the birth cohorts born around the second world war. Conclusions Gastric cancer mortality in areas with higher H. pylori seroprevalence in Tuscany (high-risk areas) showed a predominant decline by birth cohort, in particular for younger generations, possibly due to the decrease of the infection for improvement of living conditions.
Dermatofibrosarcoma Protuberans of the Breast
Authors: Lin Jong-Yueh , Sheen-Chen Shyr-Ming , Hsu Wayne , Huang Chao-Cheng , Ko Sheung-Fat , Eng Hock-Liew 
Published: February 2018

Background Dermatofibrosarcoma protuberans is an uncommon, locally aggressive but rarely metastasizing tumor of the deep dermis and subcutaneous tissue. It may occur at almost any site but is most common in the trunk and extremities. Dermatofibrosarcoma protuberans of the breast has been rarely reported. Case Presentation A 49-year-old woman without a significant medical history presented with a right breast mass that had been present for more than 10 years. Recently, progressive enlargement of the mass was noted. Physical examination showed a firm, well-defined, non-tender, mobile, erythematous 2 × 2 cm mass in the upper outer part of the right breast. Breast sonography showed a 2.3 × 1 cm slightly heteroechoic nodule with uneven anterior contours located in the dermal layer, highly suggestive of a dermal lesion. Wide excision of the mass was performed. Microscopically, the hypercellular tumor was composed of relatively monomorphic spindle cells forming a storiform pattern around the sweat glands of the deep dermis and the subcutaneous fat vacuoles. The tumor cells showed strong immunoreactivity for CD34. The final histological diagnosis was dermatofibrosarcoma protuberans. Conclusions Dermatofibrosarcoma protuberans of the breast, though uncommon, does exist. With the awareness of this entity can a prompt diagnosis be made and the disease be properly managed.
Role of Osteopontin in Breast Cancer Patients
Authors: Macrì Antonio , Versaci Antonino , Lupo Giuseppe , Trimarchi Giuseppe , Tomasello Chiara , Loddo Saverio , Sfuncia Giuseppe , Caminiti Rocco , Teti Diana , Famulari Ciro 
Published: February 2018

Aim and background In breast cancer, as in almost all neoplastic diseases, the prognosis is strictly related to the invasive capacity, local and distant, that characterizes the growth of all tumors. Since the mechanisms that regulate replication of the neoplastic cells, with consequent capacity to metastasize, are not completely known, identification of new markers represents the gold standard of research in the stratification of patients with such a pathology. Osteopontin, a specific phosphoglycoprotein isolated from extracellular bone matrix and actively involved in mechanisms of bone reabsorption, appears to play a key role in osteoclastogenesis at the level of the skeleton in some pathologic situations. It has been found that patients with metastatic bone lesions from breast or prostate cancer present, with respect to subjects without repetitive bone lesions, elevated serum levels of the protein, indicating that osteopontin could play an important role in the development and progression of the neoplastic disease at the bone level. Methods and study design The authors studied 26 patients with breast cancer, evaluating as a marker also serum osteopontin levels. Results and conclusions The results, although obtained on a small number of patients, showed that osteopontin evaluation in breast cancer patients can be a particularly interesting method of research in staging of the disease as well as in the prognosis, thereby attributing a role of a biotumoral marker also in the follow-up of the therapy.
Mutation in CNR1 Gene and VEGF Expression in Esophageal Cancer
Authors: Bedoya Fernando , Meneu Juan C , Macías María Isabel , Moreno Almudena , Enríquez-de-Salamanca Rafael , Gonzalez Enrique Moreno , Vegh Irene 
Published: February 2018

Aims and background Cannabinoid receptors have an impact on gastrointestinal function, but it remains unknown whether mutations may affect tumor susceptibility in patients with esophageal carcinoma. The aim of this study was to determine mutation in the cannabinoid receptor-1 (CNR1) gene and its relation to vascular endothelial growth factor (VEGF) expression as an angiogenic and poor prognostic factor. Methods 179 esophageal tissue samples from 69 patients (29 with esophageal cancer and 40 controls) were studied. CNR1 gene mutation (1359 G → A in codon 453) was detected with PCR, using the MspI restriction enzyme. VEGF was determined by immunoassay. Results Genotyping in control patients’ samples revealed that 24/40 were G/G wild type and 16/40 were G/A; no samples were A/A. Of the 139 tissue samples from the 29 esophageal cancer patients, 15 were G/G homozygous, 85 G/A heterozygous, 11 had an A/A genotype and 28 were without amplification. In the normal tissue adjacent to tumor, some mutations were observed. The overall survival time was reduced in patients with the A/A type in all their 5 samples, in comparison to G/G type (P = 0.04, chi-square: 4.26). VEGF expression was higher in tumor than nontumor areas (P <0.025). VEGF expression was not correlated with survival time. Conclusions Our preliminary findings in esophageal tissue showed a high frequency of G → A mutation in the CNR1 gene. No correlation between VEGF expression and gene receptor mutation was found. Patients with mutation in all their samples had a reduced survival time.
Nodal and Extranodal Soft Tissue Polymorphous Hemangioendothelioma: A Case Report and Review of the Literature
Authors: Falleti Jessica , Siano Maria , De Cecio Rossella , Somma Anna , Pettinato Guido , Insabato Luigi 
Published: February 2018

Background Polymorphous hemangioendothelioma is a rare vascular tumor of borderline malignant potential and only 10 cases have been described in the literature so far. Methods and Results We report a case of nodal and extranodal polymorphous hemangioendothelioma and review the literature. A 66-year-old man with an unremarkable past medical history was admitted for a left submandibular mass. The main nodule was composed of angiosarcoma-like areas mixed with angiomatous features; some vascular spaces with hobnail endothelium were seen. The tumor involved two adjacent lymph nodes. Immunohistochemically, the neoplastic cells were strongly positive for CD31 and vimentin. After a few months the tumor recurred and the patient was treated with radiation therapy. Conclusions Polymorphous hemangioendothelioma is a distinct entity in the hemangioendothelioma group with its own clinical and histological features.
Primary Pancreatic Lymphoma
Authors: Luo Guopei , Jin Chen , Fu Deliang , Long Jiang , Yang Feng , Ni Quanxing 
Published: February 2018

Aims and backgrounds Primary pancreatic lymphoma is non-Hodgkin lymphoma primarily involving the pancreas, which is rare in pancreatic diseases. The aim of this work is to summarize the diagnostic and therapeutic experience of primary pancreatic lymphoma. Methods We retrospectively reviewed the clinical data of 7 cases of primary pancreatic lymphoma admitted to Huashan Hospital in the past 3 years. Available English literature was also reviewed using the following terms: primary pancreatic lymphoma and pancreatic lymphoma. Results The literature review identified 157 additional cases, and a total of 164 cases had been analyzed. In this series, only 30% had a successful non-operative diagnosis. The curative rate of the surgery-adjuvant chemotherapy group was higher than that of the chemotherapy alone group. Conclusions Obtaining specimens through surgery is an effective diagnostic tool. Surgical resection in combination with postoperative chemotherapy plays a therapeutic role.
The National Center for Oncological Hadron Therapy: Status of the Project and Future Clinical use of the Facility
Authors: Orecchia Roberto , Fossati Piero , Rossi Sandro 
Published: February 2018

Aims and background Hadron therapy is an advanced radiotherapy technique that employs charged particle beams. Several particles (pions, oxygen, neon and helium ions) have been investigated in the past, but at present only protons and carbon ions are used in clinical practice. Hadron therapy has been used for more than 50 years, more than 50,000 patients have been treated worldwide, and many new facilities are being built. Indications are still a matter of debate. The Italian National Center for Oncological Hadron Therapy (CNAO) is under construction in Pavia and will begin to treat patients in the near future. Methods The CNAO will be a center capable of using both protons and carbon ions. In the first phase, three rooms with vertical and horizontal fixed beams will be available, subsequently the center will be upgraded with two more rooms equipped with a rotating gantry. The facility will use active scanning delivery systems and state-of-the-art immobilization and setup verification devices. One additional room will be devoted to physical and radiobiological research. The CNAO will be a high-patient-throughput facility capable of treating more than 3,000 patients per year. Seven areas of interest have been identified: lung cancer, liver cancer, head and neck malignancies, pediatric solid cancers, eye tumors, sarcoma and central nervous system cancers. A disease-specific working group has been created for each area and has defined selection criteria and protocols to be used at the CNAO. Two more working groups are being set up on gynecological and digestive (pancreas, biliary tract and rectum) tumors. All the patients will participate in clinical trials to establish with sound evidence the real indications for hadron therapy. National and international cooperation networks are being set up to facilitate patient referral and follow-up. A medical service is already operative to assist patients and in selected case to refer them abroad. Conclusions The CNAO will be the only carbon ion facility in Italy and will have an international basin. Close cooperation with existing oncological centers is of paramount importance to fully exploit its potential.
Changes in Glucose Metabolism during and after Radiotherapy in Non-Small Cell Lung Cancer
Authors: Giovacchini Giampiero , Picchio Maria , Schipani Stefano , Landoni Claudio , Gianolli Luigi , Bettinardi Valentino , Di Muzio Nadia , Gilardi Maria Carla , Fazio Ferruccio , Messa Cristina 
Published: February 2018

Aims and background Evaluation of the metabolic response to radiotherapy in non-small cell lung cancer patients is commonly performed about three months after the end of radiotherapy. The aim of the present study was to assess with positron emission tomography/computed tomography (PET/CT) and [18F]fluorodeoxyglucose changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer patients. Methods and study design In 6 patients, PET/CT scans with [18F]fluorodeoxyglucose were performed before (PET0), during (PET1; at a median of 14 days before the end of radiotherapy) and after the end of radiotherapy (PET2 and PET3, at a median of 28 and 93 days, respectively). The metabolic response was scored according to visual and semiquantitative criteria. Results Standardize maximum uptake at PET1 (7.9 ± 4.8), PET2 (5.1 ± 4.1) and PET3 (2.7 ± 3.1) were all significantly (P <0.05; ANOVA repeated measures) lower than at PET0 (16.1 ± 10.1). Standardized maximum uptake at PET1 was significantly higher than at both PET2 and PET3. There were no significant differences in SUVmax between PET2 and PET3. PET3 identified 4 complete and 2 partial metabolic responses, whereas PET1 identified 6 partial metabolic responses. Radiotherapy-induced increased [18F]fluorodeoxyglucose uptake could be visually distinguished from tumor uptake based on PET/CT integration and was less frequent at PET1 (n = 2) than at PET3 (n = 6). Conclusions In non-small cell lung cancer, radiotherapy induces a progressive decrease in glucose metabolism that is greater 3 months after the end of treatment but can be detected during the treatment itself. Glucose avid, radiotherapy-induced inflammation is more evident after the end of radiotherapy than during radiotherapy and does not preclude the interpretation of [18F]fluorodeoxyglucose images, particularly when using PET/CT.
Radiotherapy after Partial Laryngectomy: An Analysis of 36 Cases and a Proposal to Optimize Radiotherapy
Authors: Garibaldi Elisabetta , Bresciani Sara , Airaldi Claudia , Panaia Rocco , Ferrara Teresa , Delmastro Elena , Baiotto Barbara , Gabriele Pietro 
Published: February 2018

Aims and background Laryngeal cancer treatment options include radical surgery, “organ preservation surgery”, radiotherapy and chemotherapy. There is no proven evidence of a significant increase in late toxicity with adjuvant radiotherapy after conservative surgery. The aim of this retrospective study was to evaluate the toxicity, local-regional control and overall survival of adjuvant radiotherapy after conservative surgery. Methods A total of 36 patients was treated with radiotherapy after partial laryngectomy at the Radiotherapy Department of the Institute for Cancer Treatment and Research (IRCC) of Candiolo and of the Mauriziano Hospital in Turin, between 1994 and 2007. The postoperative treatment doses ranged from 45 to 70.2 Gy with conventional fractionation. The Kaplan-Meier method was applied for statistical analysis. The RTOG-EORTC scale was used to evaluate late and acute toxicity. Results Overall 5- and 10-year survival was 93% and 47%, respectively. Local control was 93.5% at 5 and was unchanged at 10 years. Grade 2 acute cutaneous and mucous toxicity was 41% and 62%, and grade 3, 6.9% and 3.5%, respectively. Only one patient required percutaneous endoscopic gastrostomy due to severe dysphagia and one patient required temporary tracheostomy for severe acute laryngeal edema (grade 3). Two patients experienced late toxicity greater than grade 3. The median dose to the residual larynx was 59.5 Gy (range, 45–70.2), and the median dose to the neck was 50.4 Gy (range, 39.6 −55.8). Conclusions The results of our study showed a dose-dependent increase in the late toxicity trend at doses over and above 60 Gy, which is higher than the cutoff dose reported in the literature. There was no indication from our data that adjuvant postoperative radiotherapy means additional toxicity. The use of highly conformal techniques can further reduce toxicity of the radiotherapy.
Psychosexual and Body Image Aspects of Quality of Life in Turkish Breast Cancer Patients: A Comparison of Breast Conserving Treatment and Mastectomy
Authors: Alicikus Zumre Arican , Gorken Ilknur Bilkay , Sen Rachel Cooper , Kentli Suleyman , Kinay Munir , Alanyali Hilmi , Harmancioglu Omer 
Published: February 2018

Aims and background Assessing psychosexual and body image aspects of quality of life in Turkish breast cancer patients treated by either mastectomy or breast conserving treatment (BCT). Methods The study group consisted of 112 patients who had undergone all treatment at a single institution under the care of a multidisciplinary breast team. Following surgery all patients underwent adjuvant radiotherapy with or without chemotherapy and hormone therapy. At the time of this study all patients were disease free with at least 2 years' follow-up. Twenty percent of the patients were premenopausal and 80% postmenopausal. The patients completed a questionnaire consisting of 42 questions related to their sexual relations and body image. Results Forty-one percent of sexually active patients had experienced a deterioration of sexual functioning after treatment. This was mainly due to loss of libido (80%), loss of interest in partner (54%), and sexual dissatisfaction (59%). Problems tended to develop early in the course of treatment. Decreased sexual desire was significantly more frequent in patients undergoing mastectomy versus BCT (80% vs 61%; P = 0.043) and in premenopausal versus postmenopausal patients (P= 0.024). Although 80% of patients were satisfied with their apperance as a whole, only 54% liked their naked bodies. There was no significant difference in body image scores between patients undergoing mastectomy or BCT apart from a general feeling of physical unattractive-ness in mastectomy patients (3.4 vs 2.8; P = 0.03). Conclusions Significant, similar psychosexual and body image problems occur in patients treated for breast cancer with either mastectomy or BCT. Problems arise early in the course of the disease and therefore detection and treatment of these problems should be addressed during the patients' initial assessment and at the start of treatment. These findings are similar to those reported on similar groups of treated women in American and European populations.
Increased Transglutaminase 2 and GLUT-1 Expression in Breast Tumors not Susceptible to Chemoprevention with Antioxidants
Authors: Martins Filipe C , Teixeira Filipa , Reis Ines , Geraldes Nuno , Cabrita AM Silvério , Dias Margarida F 
Published: February 2018

Goals Expression of GLUT-1 and transglutaminase 2 is increased in aggressive breast cancer, whereas claudin-1, which is expressed in normal tissues, is absent in such tumors. This experimental study was undertaken to establish the aggressiveness and prognosis of DMBA-induced mammary tumors in female Wistar rats based on the assessment of these markers. Materials and methods The rats were divided into two groups, a control group (n = 70) and a chemoprevention group (n = 70). Breast tumors were induced in both groups by administration of 7,12-dimethylbenz[a]anthracene (DMBA). The chemoprevention group also received alpha-tocopherol and a solution of micronutrients containing ascorbic acid and selenium. Neoplastic lesions of both groups were randomly selected for immunohistochemical assessment of the expression of GLUT-1, transglutaminase 2 and claudin-1. Results A higher proportion of mammary tumors expressed GLUT-1 and transglutaminase 2 in the chemoprevention group. Claudin-1 expression was absent in all tumors of both groups. Conclusions These results are suggestive of increased aggressiveness of tumors not susceptible to chemoprevention by the agents used in this study.
Spontaneous Regression of Two Giant Basal Cell Carcinomas in a Single Patient after Incomplete Excision
Authors: Rieger Ulrich M , Schlecker Christina , Pierer Gerhard , Haug Martin 
Published: February 2018

Background Spontaneous regression of small basal cell carcinoma has been reported. For giant basal cell carcinoma, however, no spontaneous regression has been described to date. Case report We present a patient with two independent giant basal cell carcinomas over the left clavicle and the lower back, measuring 7 × 12 cm and 18 × 20 cm, respectively. Both tumors were excised incompletely (R2) and the patient refused follow-up resections. After 52 and 16 months, respectively, no signs of recurrence were observed. Conclusion Incompletely excised giant basal cell carcinomas can regress spontaneously. A watch-and-wait approach after incomplete resection may be pragmatic to avoid mutilating follow-up resections in patients refusing further surgery.